Synopsis: NGL Fine-Chem Limited reported a healthy performance for Q4 FY26, driven by strong growth in revenue and operational efficiency. The pharmaceutical company posted a solid year-on-year rise in sales and profitability, supported by improved demand across key product segments. Along with the quarterly earnings, the company also announced a final dividend of Rs. 1.75 per equity share.
NGL Fine-Chem Limited is a pharmaceutical and veterinary healthcare company engaged in manufacturing APIs, intermediates, and animal healthcare products. The company has established a strong presence in domestic and international markets through its diversified product portfolio and manufacturing capabilities.
The company currently has a market capitalization of Rs. 1,532 crore, with the stock trading at Rs. 2,505 per share up by 0.12% compared to its previous close of Rs. 2,501. It touched a 52-week high of Rs. 2,768 and a low of Rs. 980. NGL Fine-Chem has a stock P/E ratio of 36.8, while its ROCE and ROE stand at 16.6 percent and 14.9 percent, respectively.
India’s pharmaceutical sector continues to remain one of the fastest-growing industries globally, supported by rising healthcare spending, increasing exports, and strong government support for domestic manufacturing. According to Bain & Company, the Indian pharmaceutical market is expected to grow from around Rs. 4.7 lakh crore in 2025 to over Rs. 10 lakh crore by 2030.
The company’s revenue from operations increased to Rs. 145 crore in Q4 FY26, compared to Rs. 126 crore in Q3 FY26 and Rs. 93 crore in Q4 FY25. This reflects a QoQ growth of around 15 percent and a strong YoY growth of nearly 56 percent.
Operating profit stood at Rs. 18 crore during Q4 FY26, compared to Rs. 20 crore in Q3 FY26 and Rs. 4 crore in Q4 FY25. The operating margin came in at 12 percent during the quarter, improving significantly from 4 percent in the corresponding quarter last year, though slightly lower than 16 percent reported in Q3 FY26.
Profit before tax for Q4 FY26 came at Rs. 15 crore, compared to Rs. 19 crore in Q3 FY26 and almost break-even levels in Q4 FY25. On the other hand, net profit stood at Rs. 11 crore during the quarter, showing a sharp turnaround from a net loss of Rs. 1 crore reported in Q4 FY25, although it declined from Rs. 15 crore in the previous quarter.
Industry Outlook
India’s pharmaceutical industry is expected to witness robust long-term growth, supported by rising demand for affordable medicines, expanding exports, and increasing healthcare awareness. The CRDMO market in India is projected to cross Rs. 1.2 lakh crore by 2028, while the domestic pharma market continues to grow at a healthy pace.
In addition, government-backed manufacturing incentives, expanding veterinary healthcare demand, and increasing global outsourcing opportunities are likely to benefit companies such as NGL Fine-Chem. The industry is also seeing rising investments in specialty chemicals, APIs, and healthcare manufacturing infrastructure.
NGL Fine-Chem delivered a steady Q4 FY26 performance with strong revenue growth and stable profitability despite rising costs. The company’s improving business momentum, healthy operational metrics, and dividend announcement indicate management’s confidence in long-term growth prospects.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post NGL Fine-Chem Q4 Revenue Surges 56% YoY to ₹145 Crore; Board Proposes ₹1.75 Final Dividend appeared first on Trade Brains.